Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vakston
Wilmington, Delaware, United Statesvakston.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead vaccine (AKS-452) is in Phase II for COVID-19. Clinical data published in Nature indicates a 90 µg subcutaneous dose safely boosts immunity in subjects previously vaccinated with mRNA or adenoviral vaccines, demonstrating strong durability, safety, and variant coverage
- Therapeutic areas
- Infectious Diseases
- Modalities
- Fc-fusion proteinBiologicVaccine
- Industry
- Biotech
02
Partnerships
LakePharma (via parent Akston Biosciences for manufacturing support)
Beyond the preview
Go deeper on Vakston.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vakston.